Cancer

News

BMS' Opdivo+Yervoy could become first choice for certain col...

Bristol-Myers Squibb’s Opdivo and Yervoy combination could become first line treatment for a small group of metastatic colorectal cancer patients with aggressive tumours, on the basis of da

News

First line kidney cancer could get crowded as Merck KGaA/Pfi...

Competition in first line kidney cancer is heating up after Germany’s Merck KGaA and Pfizer briefed the ESMO conference with detailed results of their combination of the Bavencio immunother

News

Clovis hopes to get ahead of rivals in prostate cancer with ...

Clovis’ PARP inhibitor drug Rubraca is showing promise in prostate cancer, according to data released at this year's ESMO conference, as the company hopes to steal a march on AstraZeneca an

News

Novartis wants to blaze a trail in breast cancer with PI3K d...

Novartis is preparing to file its PI3K drug combination for a certain group of breast cancer patients, after late stage trial results showed its alpelisib combination stopped the disease pr

News

Merck aims for first line kidney cancer use for Keytruda com...

Merck & Co is to request licences for its Keytruda immunotherapy in kidney cancer, following trial results showing that it improved survival in combination with Pfizer’s Inlyta compared

News